151 related articles for article (PubMed ID: 8893888)
1. An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer.
Evans WK
Semin Oncol; 1996 Oct; 23(5 Suppl 10):82-9. PubMed ID: 8893888
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.
Evans WK
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-56-S7-63. PubMed ID: 9194482
[TBL] [Abstract][Full Text] [Related]
3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
Evans WK
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer.
Earle CC; Evans WK
Cancer Prev Control; 1997 Oct; 1(4):282-8. PubMed ID: 9765752
[TBL] [Abstract][Full Text] [Related]
7. The economics of lung cancer management in Canada.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Lung Cancer; 1996 Feb; 14(1):19-29. PubMed ID: 8696718
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
Noble S; Goa KL
Drugs; 1997 Sep; 54(3):447-72. PubMed ID: 9279506
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
Earle CC; Evans WK
Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
[TBL] [Abstract][Full Text] [Related]
10. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer.
Lees M; Aristides M; Maniadakis N; McKendrick J; Botwood N; Stephenson D
Pharmacoeconomics; 2002; 20(5):325-37. PubMed ID: 11994042
[TBL] [Abstract][Full Text] [Related]
12. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
Evans WK; Le Chevalier T
Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
[TBL] [Abstract][Full Text] [Related]
14. Review of the pharmacoeconomic research on gemcitabine in the treatment of advanced non-small cell lung cancer.
Minshall ME; Liepa AM
Am J Manag Care; 1998 Nov; 4(11):1591-602. PubMed ID: 10338905
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study.
Bianco V; Rozzi A; Tonini G; Santini D; Magnolfi E; Vincenzi B; D'Angelillo R; Marchei P
Anticancer Res; 2002; 22(5):3053-6. PubMed ID: 12530041
[TBL] [Abstract][Full Text] [Related]
16. Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer.
Szczepura A
Lung Cancer; 2002 Nov; 38 Suppl 2():S21-8. PubMed ID: 12431825
[TBL] [Abstract][Full Text] [Related]
17. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
Copley-Merriman C; Corral J; King K; Whiteside R; Voi M; Dorr FA; McDonald RC
Lung Cancer; 1996 Feb; 14(1):45-61. PubMed ID: 8696720
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer.
Koch P; Johnson N; van Schaik J; Andersen S; Blatter J; Bosanquet N; Copley-Merriman K; Drings P
Anticancer Drugs; 1995 Dec; 6 Suppl 6():49-54. PubMed ID: 8718425
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
Sacristán JA; Kennedy-Martin T; Rosell R; Cardenal F; Antón A; Lomas M; Alberola V; Massuti B; Carrato A; Minshall M
Lung Cancer; 2000 May; 28(2):97-107. PubMed ID: 10717327
[TBL] [Abstract][Full Text] [Related]
20. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
